

COMING SOON

# IDYLLA™ POLE-POLD1 MUTATION ASSAY

For the detection of the hypermutated  
phenotype associated with mutations  
in POLE and POLD1



**THINK IDYLLA™  
BECAUSE TIME MATTERS**

Idylla™ POLE-POLD1 Mutation Assay is currently under development and will be launched as Research Use Only (RUO), not for use in diagnostic procedures.

# IDYLLA™ POLE-POLD1 MUTATION ASSAY



**EXPECTED BY MAY OF 2025**



Qualitative detection of **> 95% of the POLE mutations** associated with the hypermutated phenotype in endometrial and colorectal cancer samples<sup>1,2</sup>

- Exon 9: P286H, P286L, P286R, P286S, M295R, S297F
- Exon 11: F367S, F367V, D368Y
- Exon 13: V411L, L424I, L424V, P436R, M444K
- Exon 14: A456P, S459F

Additionally, one mutation in **POLD1** is detected: S478N



For use on the **fully automated Idylla™ Platform**  
**On-demand testing** (no sample batching required)



Directly from **FFPE** tissue sections



Results in **only 2 hours**  
Approximately **3 minutes** hands-on-time

## REFERENCES

(1) León-Castillo, A. et al. (2020). Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. *The Journal of pathology*, 250(3), 312–322. <https://doi.org/10.1002/path.5373>

(2) Ambrosini, M. et al. (2024). Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. *Ann Oncol.*, 35(7), 643–655. <https://doi.org/10.1016/j.annonc.2024.03.009>

Biocartis NV  
Generaal De Wittelaan 11B  
2800 Mechelen, Belgium  
+32 15 632 888

Biocartis US Inc.  
2 Pierce Place Suite 1510  
Itasca, IL 60143, US  
+1 (844) 443-9552

Follow us on     
[www.biocartis.com](http://www.biocartis.com)  
[customerservice@biocartis.com](mailto:customerservice@biocartis.com)  
[customerserviceUS@biocartis.com](mailto:customerserviceUS@biocartis.com)

Idylla™ POLE-POLD1 Mutation Assay is currently under development and will be launched as Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. Idylla™ is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative.  
© February 2025, Biocartis NV. All rights reserved.